Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $118.75 USD
Change Today 0.00 / 0.00%
Volume 0.0
AKBLF On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
Berlin
OTC US
As of 4:30 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

alk-abello a/s (AKBLF) Snapshot

Open
--
Previous Close
$118.75
Day High
--
Day Low
--
52 Week High
07/31/14 - $143.25
52 Week Low
12/11/14 - $113.00
Market Cap
1.2B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
9.2M
EX-Date
03/13/15
P/E TM
--
Dividend
$4.80
Dividend Yield
0.59%
Current Stock Chart for ALK-ABELLO A/S (AKBLF)

Related News

No related news articles were found.

alk-abello a/s (AKBLF) Related Businessweek News

No Related Businessweek News Found

alk-abello a/s (AKBLF) Details

ALK-Abelló A/S, a pharmaceutical company, engages in the research and development, production, and sale of products for the diagnosis, prevention, and treatment of allergies worldwide. The company offers allergy immunotherapy products as injections, sublingual drops, and sublingual tablets for various allergies, including grass, ragweed, house dust mite, tree, cat, bee, and wasp. It also offers adrenaline auto-injectors for the treatment of severe allergic reactions. In addition, the company’s development programs include GRAZAX for grass allergic (ARC) and asthma prevention; GRASTEK for grass ARC; RAGWITEK for ragweed ARC; house dust mite (HDM) sublingual tablet-based allergy immunotherapy (SLIT)-tablets for HDM asthma and rhinitis; tree SLIT-tablet for tree ARC; and Japanese cedar SLIT-tablet for cedar tree ARC. It has strategic partnership agreements with Merck & Co., Inc. and Torii Pharmaceutical Co., Ltd. to develop, register, and commercialize SLIT-tablets in North America and Japan. The company was founded in 1923 and is headquartered in Hørsholm, Denmark.

1,829 Employees
Last Reported Date: 05/5/15
Founded in 1923

alk-abello a/s (AKBLF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

alk-abello a/s (AKBLF) Key Developments

Alk Abello A/S and Merck Announce Encouraging Results from Phase III Allergic Rhinitis Trial

Alk Abello A/S has announced encouraging results from its partner, Merck, or MSD's North-American Phase III clinical trial of ALK's investigational sublingual allergy immunotherapy tablet, or SLIT-tablet, for the treatment of house dust mite, or HDM, allergic rhinitis. The trial demonstrated a statistically significant improvement in the primary endpoint in favour of HDM SLIT-tablet compared with placebo. The primary endpoint of the trial was to demonstrate a reduction in the 'Total Combined Rhinitis Score' (TCRS) which is the sum of the average daily rhinitis symptom score and the average daily medication score. The trial also showed that the treatment was generally well tolerated. The trial, a randomised, multi-centre, placebo controlled, double-blind, comparative trial, was initiated by MSD in March 2014 to further investigate the safety and efficacy of the HDM SLIT-tablet in patients with HDM allergic rhinitis. It involved approximately 1,500 patients in the USA and Canada and is part of the world's large ever allergy immunotherapy development programme, which also includes trials in Europe and Japan. MSD has informed ALK that they now plan to discuss the data and the plans for a regulatory submission of a Biological License Application (BLA) for the HDM SLIT-tablet with the FDA. The HDM SLIT-tablet is currently undergoing regulatory reviews in Europe and Japan based on a combined clinical development programme involving more than 4,000 patients, including the completion of two positive Phase III clinical trials for the treatment of HDM allergic rhinitis and one positive Phase III trial for the treatment of HDM allergic asthma.

ALK-Abelló A/S Presents at Nordic Mid/Small Cap Seminar, Jun-02-2015

ALK-Abelló A/S Presents at Nordic Mid/Small Cap Seminar, Jun-02-2015 . Venue: Stockholm, Sweden.

ALK-Abelló A/S Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 08:40 AM

ALK-Abelló A/S Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 08:40 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Flemming Pedersen, Chief Financial Officer, Executive Vice President and Member of Management Board.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKBLF:US $118.75 USD 0.00

AKBLF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKBLF.
View Industry Companies
 

Industry Analysis

AKBLF

Industry Average

Valuation AKBLF Industry Range
Price/Earnings 51.8x
Price/Sales 3.4x
Price/Book 3.4x
Price/Cash Flow 48.4x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALK-ABELLO A/S, please visit www.alk-abello.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.